Claude designs 318,484 scorpion antivenom candidates

The scorpion work follows an earlier study in which Claude designed mini-binders against 14 of 15 target proteins, achieving hit rates of 22 to 35 percent compared to the typical 10 to 15 percent. That prior result provides context for the current effort: the same AI environment, Claude Science, produced a large batch of designs and a smaller set of lab-validated binders. The research team steered the work with additional instructions after an initial 24-hour autonomous run, suggesting a human-in-the-loop process rather than full automation. External experts Susana Vázquez Torres and Timothy P. Jenkins described the work as a promising first step, and two independent labs confirmed the results, which may lend credibility to the findings. However, whether the binders actually function as an antivenom has not been tested, leaving the practical medical payoff uncertain.